Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

S. Karim, K. Ding, P. Bradbury, P. Ellis, N. Mittman, X. Xiaoqun Sun, M. Millward, G. Liu, S. Sun, M. R. Stockler, V. Cohen, N. Blais, R. Sangha, M. Boyer, R. Sasidharan, C. Lee, F. A. Shepherd, G. Goss, L. Seymour, N. B. Leighl

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume28
Publication statusPublished - Sep 2017
Externally publishedYes
Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
Duration: 8 Sep 201712 Sep 2017

Cite this

Karim, S., Ding, K., Bradbury, P., Ellis, P., Mittman, N., Sun, X. X., ... Leighl, N. B. (2017). Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. Annals of Oncology, 28.